US 12,332,251 B2
Metabolic biomarkers for predicting responsiveness to FGF-18 compound
Christoph H. Ladel, Darmstadt (DE); Hans Guehring, Geisenheim (DE); Anne-Christine Bay-Jensen, Copenhagen (DK); Morten Karsdal, Copenhagen (DK); and Per Qvist, Copenhagen (DK)
Assigned to Merck Patent GmbH, Darmstadt (DE)
Filed by MERCK PATENT GMBH, Darmstadt (DE)
Filed on Sep. 7, 2022, as Appl. No. 17/930,389.
Application 17/930,389 is a continuation of application No. 16/650,881, granted, now 11,513,128, previously published as PCT/EP2018/076395, filed on Sep. 28, 2018.
Claims priority of application No. 17194220 (EP), filed on Sep. 29, 2017; and application No. 18169324 (EP), filed on Apr. 25, 2018.
Prior Publication US 2023/0251271 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); A61K 38/18 (2006.01); A61P 19/04 (2006.01)
CPC G01N 33/6887 (2013.01) [A61K 38/1825 (2013.01); A61P 19/04 (2018.01); G01N 2333/78 (2013.01); G01N 2800/105 (2013.01); G01N 2800/52 (2013.01)] 12 Claims
 
1. A method for treating a subject having a cartilage disorder characterized by articular cartilage injury or loss of articular cartilage, with an FGF-18 compound, comprising the following steps:
a) determining, from a sample from said subject, the quantity of at least one biomarker selected from the group consisting of CTX-II (C-terminal telopeptide of type II collagen) and ProC2 (neo-epitope of Collagen type II), and
b) administering intraarticularly the FGF-18 compound in an amount that is about 30-100 μg to the subject having lower than 350±2SD ng/mmol of CTX-II, and/or lower than 4.2±2SD ng/ml of ProC2, and
wherein the FGF-18 compound comprises amino acid residues 28-196 of SEQ ID NO: 1, optionally fused to a heterologous protein or chemical compound.